Regeneron Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.21B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B |
| Net Product Sales | — | $8.53B | $8.38B | $8.10B | $12.12B | $5.13B | — | — |
| Collaboration Revenue | — | $5.32B | $4.40B | $3.78B | $3.59B | $3.17B | — | — |
| Other Revenue | — | $370.2M | $346.5M | $301.2M | $364.4M | $193.5M | — | — |
| Cost of Revenue | — | — | — | — | — | — | $402.8M | $237.5M |
| Gross Profit | — | — | — | — | — | — | $6.15B | $4.91B |
| Gross Margin | — | — | — | — | — | — | 93.9% | 95.4% |
| Operating Expenses | ||||||||
| Research & Development | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B |
| SG&A Expense | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B |
| Operating Margin | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 33.7% | 49.3% |
| Interest Expense | — | — | $73.0M | $59.4M | $57.3M | $56.9M | $30.2M | $28.2M |
| Pretax Income | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B |
| Income Tax Expense | $725.8M | $367.3M | $245.7M | $520.4M | $1.25B | $297.2M | $313.3M | $109.1M |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B |
| Net Margin | 31.4% | 31.0% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% |
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 |
| Shares Outstanding (Basic) | 104.6M | 107.9M | 106.7M | 107.1M | 105.7M | 107.6M | 109.2M | 107.9M |
| Shares Outstanding (Diluted) | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |